Animal Health Adjacencies

Animal Health adjacencies are the markets that surround the core Animal Health Pharmaceutical industry, including veterinary diagnostics, animal genetics, pet and livestock nutrition, animal MedTech, veterinary services and clinic consolidation, livestock precision farming, animal pharmaceutical APIs and excipients, and veterinary distribution. These segments share customers, channels, and structural tailwinds with core Animal Health but operate under distinct commercial, regulatory, and competitive dynamics.

Several structural forces are driving capital into adjacent sectors: humanization and premiumization of pet care, growing demand for preventive and data-driven veterinary medicine, fragmentation in veterinary services creating buy-and-build opportunities, sustainability pressures reshaping livestock production, and the entry of medtech, biotech, and digital health innovation into animal applications. Many adjacencies remain less consolidated than the core therapeutics market, offering attractive growth and roll-up economics for Private Equity and strategic acquirers.

Veterinary services consolidation, veterinary diagnostics, pet nutrition (particularly premium and prescription segments), and animal MedTech have seen sustained M&A activity in recent years. Private Equity firms have been especially active in veterinary clinic platforms and point-of-care diagnostics, while strategic acquirers continue to pursue genetics, nutritional health, and specialty distribution to round out their portfolios.

Each adjacency has its own buyer, channel, and competitive logic. Diagnostics decisions are driven by clinic workflow and reimbursement; nutrition by retail and veterinary recommendation dynamics; MedTech by capital cycle and clinical adoption; vet services by site-level economics and labor markets. Applying a generic Animal Health Pharmaceutical playbook to these segments often leads to flawed strategy, which is why sector-specific commercial expertise matters.

Commercial due diligence in adjacencies requires combining traditional market sizing, competitive analysis, and customer research with segment-specific lenses -for example, point-of-care vs. reference lab dynamics in diagnostics, premium vs. mass-market positioning in pet nutrition, or site-level unit economics in vet clinic platforms. The objective is the same as in core Animal Health CDD: a defensible view of market attractiveness, growth sustainability, and value creation potential, calibrated to the specific adjacency.

Stonehaven Cozmix Group advises Animal Health corporates expanding beyond their core, private equity sponsors evaluating platforms and add-ons, family offices, and emerging companies scaling within specific adjacencies. Engagements range from commercial growth strategy and product assessment through segmentation, M&A due diligence, transactions advisory, and post-acquisition value creation.